Comparing Biosig Technologies (NASDAQ:STEX) and Profusa (NASDAQ:PFSA)

Biosig Technologies (NASDAQ:STEX) and Profusa (NASDAQ:PFSA) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Insider and Institutional Ownership

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 11.4% of Profusa shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Biosig Technologies has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Profusa has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Biosig Technologies and Profusa, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1	0	0	0	1.00
Profusa	1	0	0	0	1.00

Profitability

This table compares Biosig Technologies and Profusa’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	N/A	-64.96%
Profusa	N/A	N/A	-880.32%

Valuation and Earnings

This table compares Biosig Technologies and Profusa”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40,000.00	9,907.86	-$10.33 million	($1.35)	-1.64
Profusa	N/A	N/A	-$8.71 million	($167.67)	-0.01

Profusa has lower revenue, but higher earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Summary

Biosig Technologies beats Profusa on 5 of the 8 factors compared between the two stocks.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.